Triumvira Immunologics
Triumvira Immunologics is a Healthcare & Life Sciences startup based in the United States, most recent round Series A, 1 tracked investor.
About Triumvira Immunologics
Triumvira Immunologics is a startup founded in 2018 based in the United States. Its most recent tracked round is Series A. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.
Triumvira Immunologics develops T-Cell Antigen Coupler (TAC) therapeutics — autologous and allogeneic cell therapies designed to treat solid tumors and blood cancers with an improved safety profile versus conventional CAR‑T approaches. In March 2021 the company submitted an IND to the FDA and began enrolling patients in a Phase I trial in collaboration with MD Anderson Cancer Center.
Explore Triumvira Immunologics's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.